EMPAGLIFORM 5-500 mg – Dual-Mechanism Type 2 Diabetes Treatment (Hikma)

EMPAGLIFORM 5-500 mg, manufactured by Hikma, is a combination therapy designed for adult patients with type 2 diabetes mellitus (T2DM) who require better blood sugar control.

This formulation combines:

• Empagliflozin 5 mg – A sodium-glucose co-transporter-2 (SGLT2) inhibitor
• Metformin 500 mg – A first-line insulin sensitizer

Together, they deliver powerful, balanced glucose management with a low risk of hypoglycemia.

Indications – When to Use EMPAGLIFORM 5-500 mg

Used in adults with type 2 diabetes to:

✔ Improve blood glucose control
✔ Reduce HbA1c
✔ Support mild weight reduction
✔ Provide cardiovascular and renal protection
✔ Add to Metformin therapy when single treatment is not enough

How EMPAGLIFORM 5-500 mg Works

1. Empagliflozin 5 mg (SGLT2 Inhibitor)

• Promotes glucose elimination through urine
• Works independently of insulin
• Helps reduce weight
• May lower blood pressure slightly
• Provides heart and kidney protection in diabetic patients

2. Metformin 500 mg

• Reduces hepatic glucose production
• Improves insulin sensitivity
• Enhances peripheral glucose uptake
• Considered the foundation of T2DM treatment

The combination attacks high blood sugar from two complementary pathways.

Dosage & Administration

• Typically, one tablet twice daily, or as advised by the doctor
• Take with meals to minimize stomach discomfort (Metformin effect)
• Swallow whole — do not crush or chew
• Maintain good hydration

Side Effects

Common:

• Increased urination
• Stomach upset (Metformin)
• Nausea or diarrhea
• Thirst
• Headache

Less common but important:

• Genital yeast infections
• Urinary tract infections
• Lactic acidosis (rare but serious)
• Dehydration

Seek medical help if symptoms are severe.

Do NOT Use If:

• Patient has type 1 diabetes
• Severe kidney impairment
• Severe liver disease
• History of metabolic acidosis
• Pregnancy or breastfeeding (unless doctor approves)
• Allergy to Empagliflozin or Metformin

Key Benefits of EMPAGLIFORM 5-500 mg

• Effective dual-action control of blood sugar
• Low hypoglycemia risk
• Supports modest weight reduction
• Works well in early or moderate T2DM
• Convenient dose combining two medicines
• Trusted Hikma pharmaceutical quality

Disclaimer: This information is for educational purposes only and does not replace medical advice. Use as directed by a healthcare professional.